

FORM PTO-1390 (Modified)
(REV 11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES

DEX-0150

DESIGNATED/ELECTED OFFICE (DO/EO/US)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

CONCERNING A FILING UNDER 35 U.S.C. 371

09/762021

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/US99/16357

20 July 1999

4 August 1998

TITLE OF INVENTION

A Novel Method of Diagnosing, Monitoring, Staging, Imaging and Treating Colon Cancer

APPLICANT(S) FOR DO/EO/US

SUN, Yongming et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1)
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau)
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). - **Unexecuted**
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

- 1) Courtesy copy of International Application
- 2) Executed Verified Statement Claiming Small Entity Status
- 3) Return Post Card

"Express Mail" Label No. **EL722986068US**
Date of Deposit **February 1, 2001**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231.

By Deborah Ehret
Typed Name: Deborah Ehret



Rec'd PCT/PTO 04 SEP 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#7

Attorney Docket No.: DEX-0150
Inventors: Sun et al.
Serial No.: 09/762,021
Filing Date: February 1, 2001
Examiner: Not yet assigned
Group Art Unit: Not yet assigned
Title: A Novel Method of Diagnosing,
Monitoring, Staging, Imaging and
Treating Colon Cancer

"Express Mail" Label No. EL 722985500 US
Date of Deposit September 4, 2001

I hereby certify that this paper is being deposited
with the United States Postal Service "Express Mail
Post Office to Addressee" service under 37 CFR 1.10
on the date indicated above and is addressed to the
Assistant Commissioner for Patents, Washington,
D.C. 20231.

By Kathleen A. Tyrrell
Typed Name: Kathleen A. Tyrrell

BOX SEQUENCE
Assistant Commissioner for Patents
Washington, DC 20231

Sir:


AMENDMENT

In reply to the Notification to Comply with Requirements for
Patent Applications containing Nucleotide Sequence and/or Amino
Acid Sequence Disclosure dated **August 2, 2001**, a response to which
is due **September 2, 2001**, it is requested that the Sequence Listing
of the instant specification be deleted and replaced with the
amended Sequence Listing provided herewith. The replacement
Sequence Listing has been amended to conform with the current
Sequence Listing Rules. However, data presented in the Sequence

09/04/01 09:00

Listing is identical to that originally filed. Thus, no new matter has been added by this amendment.

Respectfully submitted,



Kathleen A. Tyrrell
Registration No. 38,350

Date: September 4, 2001

LICATA & TYRRELL P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Rec'd PCT/PTO 04 SEP 2001



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0150
Inventors: Sun et al.
Serial No.: 09/762,021
Filing Date: February 1, 2001
Examiner: Not yet assigned
Group Art Unit: Not yet assigned
Title: A Novel Method of Diagnosing,
Monitoring, Staging, Imaging and
Treating Colon Cancer

"Express Mail" Label No. EL 722985500 US
Date of Deposit - September 4, 2001

I hereby certify that this paper is being deposited with
the United States Postal Service "Express Mail Post Office
to Addressee" service under 37 CFR 1.10 on the date
indicated above and is addressed to the Assistant Commissioner for
Patents, Washington, D.C. 20231.

By Kathleen A. Tyrrell
Typed Name: Kathleen A. Tyrrell

BOX SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825**

- () I hereby state, in accordance with the requirements of 37
C.F.R. §1.821(f), that the contents of the paper and
computer readable copies of the Sequence Listing, submitted
in accordance with 37 CFR §1.821(c) and (e), respectively
are the same.
- () I hereby state that the submission filed in accordance with
37 CFR §1.821(g) does not include new matter.

- () I hereby state that the submission filed in accordance with **37 CFR §1.821(h)** does not include new matter or go beyond the disclosure in the international application as filed.
- (XX) I hereby state that the amendments, made in accordance with **37 CFR §1.825(a)**, included in the substitute sheet(s) of the Sequence Listing were made to conform with the current Sequence Listing rules. I hereby state that the substitute sheet(s) of the Sequence Listing does not include new matter.
- (XX) I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(b)**, is the same as the amended Sequence Listing.
- (XX) I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(d)**, contains identical data to that originally filed.

Respectfully submitted,




Kathleen A. Tyrrell
Registration No. 38,350

Date: **September 4, 2001**

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

| | | |
|---------------------|-----------------------|----------------|
| U.S. APPLICATION NO | FIRST NAMED APPLICANT | ATTY DOCKET NO |
| 09/762021 | SUN Y | DEX-0150 |

LICATA & TYRRELL
66 E MAIN STREET
MARLTON, NJ 08054Docket System ☒
Status Report ☒
Docket Book ☒

INTERNATIONAL APPLICATION NO

PCT/US99/16357

I.A. FILING DATE

PRIORITY DATE

20 JUL 99

04 AUG 98

DATE MAILED

02 AUG 2001

Notice to
Comply
9-2-01
2-2-02**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- ☒ The application fails to comply with the requirements of 37 CFR 1.821-1.825.
- ☐ This application does not contain, a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- ☐ A copy of the "Sequence Listing" in computer readable format has not been submitted as required by 37 CFR 1.821(e).
- ☒ A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e)
- ☐ Other: _____

APPLICANT MUST PROVIDE:

- ☒ An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- ☐ An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- ☒ A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

**FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE
CALL:**

(703) 308-4216, for Rules interpretation,
(703) 308-4212, for CRF submission help.
(703) 287-0200, for PatentIn software help.

Barbara A. Campbell

Telephone: 703-305-3631

FORM PCT/DO/EO/920 (March 2001)



SEQUENCE LISTING

<110> Sun, Yongming
Macina, Roberto A
Recipon, Herve
DIADEXUS LLC

<120> A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING,
IMAGING AND TREATING COLON CANCER

<130> DEX-0039

<140>

<141>

<150> 60/095,231

<151> 1998-08-04

<160> 3

<170> PatentIn Ver. 2.0

<210> 1

<211> 1710

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1704)

<223> c,a,t or g

<400> 1

ggcagagcga ctgaagacca gcctgcagaa ggctctggag gaagagctgg agcaaagacc 60
tcgacttgga ggccttcagc caggccagga cagatggagg gggcctgcta tggaaaggcc 120
gctccctatg gagcaggcac gctatctgga gccggggatc cctccagaac agccccacca 180
gaggacccta gagcacagcc tcccaccatc cccaaggccc ctgccacgcc acaccagtgc 240
ccgagaacca agtgccttta ctctgcctcc tccaaggcgg tccctcttccc ccgaggaccc 300
agagaggggac gaggaagtgc tgaaccatgt cctaagggac attgagctgt tcatgggaaa 360
gctggagaag gcccaggcaa agaccagcag gaagaagaaa tttgggaaaa aaaacaagga 420
ccagggaggt ctcaccagg cagagtacat tgactgcttc cagaagatca agtacagctt 480
caacctcctg ggaaggctgg ccacctggct gaaggagaca agtgcccctg agctcgtaca 540
catcctcttc aagtccctga acttcacatc ggccagggtgc cctgaggctg gcctagcagc 600
ccaagtgatc tcaccctcc tcacccttaa agctatcaac ctgctacagt cctgtctaag 660
cccacctgag agtaaccttt ggatgggggtt gggcccagcc tggaccacta gccggggcca 720
ctggacaggc gatgagcccc tgccctacca acccacattc tcagatgact ggcaacttcc 780
agagccctcc agccaagcac ccttaggata ccaggaccct gtttcccttc ggcggggaag 840
tcataggtta gggagcacct cacactttcc tcaggagaag acacacaacc atgaccctca 900

```

gcttggggac cccaactcca ggccctccag ccccaaactt gccagccag ccctgaaaat 960
gcaagtcttg tacgagtttg aagctaggaa cccacgggaa ctgactgtgg tccagggaga 1020
gaagctggag gttctggacc acagcaagcg gtgggtggctg gtgaagaatg aggcgggacg 1080
gagcggctac attccaagca acatcctgga gcccctacag ccggggaccc ctgggaccca 1140
gggccagtca ccctctcggg ttccaatgct tgcacttagc tcgaggcctg aagaggtcac 1200
agactggctg caggcagaga acttctccac tgccacgggtg aggacacttg ggtccctgac 1260
ggggagccag ctacttcgca taagacctgg ggagctacag atgctatgtc cacaggaggc 1320
cccacgaatc ctgtcccggc tggaggctgt cagaaggatg ctggggataa gcccttaggc 1380
accagcttag acacctccaa gaaccaggcc ccgctgatgc aagatggcag atctgatacc 1440
cattagagcc ccgagaattc ctcttctgga tcccagtttg cagcaaacc caccaccag 1500
ctcacacagc aaaaacaatg gacaggccca gaggctgaag caaacagtgt cccttctggc 1560
tgtgttgagg cctccccagt aaccacctat ttattttacc tctttcccaa acctggagca 1620
tttatgccta ggcttgtcaa gaatctgttc agtccctctc cttctcaata aaagcatctt 1680
caagcttgta aaaaaaaaaa taangataaa 1710

```

```

<210> 2
<211> 1109
<212> DNA
<213> Homo sapiens

```

```

<400> 2
gggaaccacc ttctgtagga cagtcaccag gccagatcca gaagcctctc taggctccag 60
ctttctctgt ggaagatgac agcaattata gcaggacctt gccaggctgt cgaagagatt 120
ccgcaataaa actttgccag tgggaagtac ctagtgaac ggcctaagat gccacttctt 180
ctcatgtccc aggcttgagg ccctgtgggtc cccatccttg ggagaagtca gctccagcac 240
catgaagggc atcctcggtg ctggtatcac tgcagtgttt gttgcagctg tagaatctct 300
gagctgcgtg cagtgttaatt catgggaaaa atcctgtgtc aacagcattg cctctgaatg 360
tccctcacat gccaacacca gctgtatcag ctctcagcc agctcctctc tagagacacc 420
agtcagatta taccagaata tgttctgctc agcggagaac tgcagtgagg agacacacat 480
tacagccttc actgtccacg tgtctgctga agaacacttt cattttgtaa gccagtgtg 540
ccaaggaaaag gaatgcagca acaccagcga tgccctggac cctccccctga agaacgtgtc 600
cagcaacgca gagtgccttg cttgttatga atctaattga acttctgtc gtgggaagcc 660
ctggaaatgc tatgaagaag aacagtgtgt ctttctagtt gcagaactta agaatgacat 720
tgagtctaag agtctcgtgc tgaaaggctg ttccaacgtc agtaacgcca cctgtcagtt 780
cctgtctggt gaaaacaaga ctcttgagg agtcatcttt cgaaagtttg agtgtgcaa 840
tgtaaacagc ttaaccccca cgtctgcacc aaccacttcc cacaacgtgg gctccaaagc 900
ttccctctac ctcttgcccc ttgccagcct ccttctctcg ggactgctgc cctgaggtcc 960
tggggctgca ctttgccag caccctattt ctgcttctct gaggtccaga gcacccctg 1020
cgggtgctgac accctctttc cctgctctgc ccggtttaac tgcccagtaa gtgggagtca 1080
caggtctcca ggcaatgccg acagctgcc 1109

```

```

<210> 3
<211> 1141
<212> DNA
<213> Homo sapiens

```

```

<400> 3
cagagaaaaga ggaaacatag aggtgccaaa ggaacaaaga cataatgatg tcaccaagc 60

```


caacaagcca tgctgaagta aatgaaacca tacccaaccc ttaccacacca agcagcttta 120
 tggctcctgg atttcaacag cctctgggtt caatcaactt agaaaaccaa gctcaggggtg 180
 ctacgcgtgc tcagccctat ggcattcacat ctccgggaat ctttgctagc agtcaaccgg 240
 gtcaaggaaa tatacaaatg ataaatccaa gtgtgggaac agcagtaatg aactttaaag 300
 aagaagcaaa ggcactaggg gtgatccaga tcatgggttg attgatgcac attgggtttg 360
 gaattgtttt gtgtttaata tccttctctt ttagagaagt attaggtttt gcctctactg 420
 ctgttattgg tggataccca ttctgggggtg gcctttcttt tattatctct ggctctctct 480
 ctgtgtcagc atccaaggag ctttcccggt gtctggtgaa aggcagcctg ggaatgaaca 540
 ttgttagttc tatcttggcc ttcataggag tgattctgct gctgggtggat atgtgcatca 600
 atggggtagc tggccaagac tactgggccc tgctttctgg aaaaggcatt tcagccacgc 660
 tgatgatctt ctccctcttg gagttcttcg tagcttgctc cacagcccat tttgcccaacc 720
 aagcaaacac cacaaccaat atgtctgtcc tggttattcc aaatatgtat gaaagcaacc 780
 ctgtgacacc agcgtcttct tcagctcctc ccagatgcaa caactactca gctaattgcc 840
 ctaaataagta aaagaaaaag gggatatcagt ctaatctcat ggagaaaaac tacttgcaaa 900
 aacttcttaa gaagatgtct ttattgtct acaatgattt ctagtcttta aaaactgtgt 960
 ttgagatttg tttttagggt ggtcgctaata gatggctgta tctcccttca ctgtctcttc 1020
 ctacattacc actactacat gctggcaaag gtgaaggatc agaggactga aaaatgattc 1080
 tgcaactctc ttaaagttag aaatgtttct gttcatatta ctttttcctt aataaaatgt 1140
 c 1141

A NOVEL METHOD OF DIAGNOSING,
MONITORING, STAGING, IMAGING AND TREATING COLON CANCER

FIELD OF THE INVENTION

This invention relates, in part, to newly developed
5 assays for detecting, diagnosing, monitoring, staging,
prognosticating, imaging and treating cancers, particularly
colon cancer.

BACKGROUND OF THE INVENTION

10 Cancer of the colon is a highly treatable and often
curable disease when localized to the bowel. It is one of the
most frequently diagnosed malignancy in the United States as
well as the second most common cause of cancer death. Surgery
is the primary treatment and results in cure in approximately
15 50% of patients. However, recurrence following surgery is a
major problem and often is the ultimate cause of death.

The prognosis of colon cancer is clearly related to the
degree of penetration of the tumor through the bowel wall and
the presence or absence of nodal involvement. These two
20 characteristics form the basis for all staging systems
developed for this disease. Treatment decisions are usually
made in reference to the older Duke's or the Modified Astler-
Coller (MAC) classification scheme for staging.

Bowel obstruction and bowel perforation are indicators
25 of poor prognosis in patients with colon cancer. Elevated
pretreatment serum levels of carcinoembryonic antigen (CEA)
and of carbohydrate antigen 19-9 (CA 19-9) also have a
negative prognostic significance.

Age greater than 70 years at presentation is not a
30 contraindication to standard therapies. Acceptable morbidity
and mortality, as well as long-term survival, are achieved in
this patient population.

- 2 -

Because of the frequency of the disease (approximately 160,000 new cases of colon and rectal cancer per year), the identification of high-risk groups, the demonstrated slow growth of primary lesions, the better survival of early-stage lesions, and the relative simplicity and accuracy of screening tests, screening for colon cancer should be a part of routine care for all adults starting at age 50, especially those with first-degree relatives with colorectal cancer.

Procedures used for detecting, diagnosing, monitoring, staging, and prognosticating colon cancer are of critical importance to the outcome of the patient. For example, patients diagnosed with early colon cancer generally have a much greater five-year survival rate as compared to the survival rate for patients diagnosed with distant metastasized colon cancer. New diagnostic methods which are more sensitive and specific for detecting early colon cancer are clearly needed.

Colon cancer patients are closely monitored following initial therapy and during adjuvant therapy to determine response to therapy and to detect persistent or recurrent disease of metastasis. There is clearly a need for a colon cancer marker which is more sensitive and specific in detecting colon cancer, its recurrence, and progression.

Another important step in managing colon cancer is to determine the stage of the patient's disease. Stage determination has potential prognostic value and provides criteria for designing optimal therapy. Generally, pathological staging of colon cancer is preferable over clinical staging because the former gives a more accurate prognosis. However, clinical staging would be preferred were it at least as accurate as pathological staging because it does not depend on an invasive procedure to obtain tissue for pathological evaluation. Staging of colon cancer would be improved by detecting new markers in cells, tissues, or bodily

- 3 -

fluids which could differentiate between different stages of invasion.

In the present invention methods are provided for detecting, diagnosing, monitoring, staging, prognosticating, 5 *in vivo* imaging and treating colon cancer via three (3) Colon Specific Genes (CSGs). The 3 CSGs refer, among other things, to native proteins expressed by the genes comprising the polynucleotide sequences of any of SEQ ID NO: 1, 2, or 3. In the alternative, what is meant by the 3 CSGs as used herein, 10 means the native mRNAs encoded by the genes comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, or 3 or it can refer to the actual genes comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, or 3.

Other objects, features, advantages and aspects of the 15 present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various 20 changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

SUMMARY OF THE INVENTION

25 Toward these ends, and others, it is an object of the present invention to provide a method for diagnosing the presence of colon cancer by analyzing for changes in levels of CSG in cells, tissues or bodily fluids compared with levels of CSG in preferably the same cells, tissues, or bodily fluid 30 type of a normal human control, wherein an increase in levels of CSG in the patient versus normal human control is associated with colon cancer.

Further provided is a method of diagnosing metastatic colon cancer in a patient having such cancer which is not

- 4 -

known to have metastasized by identifying a human patient suspected of having colon cancer that has metastasized; analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, 5 tissues, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

10 Also provided by the invention is a method of staging colon cancer in a human which has such cancer by identifying a human patient having such cancer; analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing CSG levels in such cells, tissues, or bodily fluid 15 with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CSG is associated with a 20 cancer which is regressing or in remission.

Further provided is a method of monitoring colon cancer in a human having such cancer for the onset of metastasis. The method comprises identifying a human patient having such cancer that is not known to have metastasized; periodically 25 analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissue, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the 30 patient versus the normal human control is associated with a cancer which has metastasized.

Further provided is a method of monitoring the change in stage of colon cancer in a human having such cancer by looking at levels of CSG in a human having such cancer. The 35 method comprises identifying a human patient having such

T09000" T2029260

- 5 -

cancer; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissue, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CSG is associated with a cancer which is regressing or in remission.

10 Further provided are antibodies against the CSGs or fragments of such antibodies which can be used to detect or image localization of the CSGs in a patient for the purpose of detecting or diagnosing a disease or condition. Such antibodies can be polyclonal or monoclonal, or prepared by
15 molecular biology techniques. The term "antibody", as used herein and throughout the instant specification is also meant to include aptamers and single-stranded oligonucleotides such as those derived from an *in vitro* evolution protocol referred to as SELEX and well known to those skilled in the art.
20 Antibodies can be labeled with a variety of detectable labels including, but not limited to, radioisotopes and paramagnetic metals. These antibodies or fragments thereof can also be used as therapeutic agents in the treatment of diseases characterized by expression of a CSG. In therapeutic
25 applications, the antibody can be used without or with derivatization to a cytotoxic agent such as a radioisotope, enzyme, toxin, drug or a prodrug.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in
30 the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the
35 disclosed invention will become readily apparent to those

- 6 -

skilled in the art from reading the following description and from reading the other parts of the present disclosure.

DESCRIPTION OF THE INVENTION

The present invention relates to diagnostic assays and methods, both quantitative and qualitative for detecting, diagnosing, monitoring, staging, and prognosticating cancers by comparing levels of CSG with those of CSG in a normal human control. What is meant by levels of CSG as used herein, means levels of the native protein expressed by the genes comprising the polynucleotide sequence of any of SEQ ID NO: 1, 2, or 3. In the alternative, what is meant by levels of CSG as used herein, means levels of the native mRNA encoded by any of the genes comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, or 3 or levels of the gene comprising any of the polynucleotide sequence of SEQ ID NO: 1, 2, or 3. Such levels are preferably measured in at least one of, cells, tissues and/or bodily fluids, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for diagnosing over-expression of any one of the CSG proteins compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of cancers, including colon cancer. Any of the 3 CSGs may be measured alone in the methods of the invention, or all together or any combination of the three.

All the methods of the present invention may optionally include measuring the levels of other cancer markers as well as CSG. Other cancer markers, in addition to CSG, useful in the present invention will depend on the cancer being tested and are known to those of skill in the art.

30

Diagnostic Assays

The present invention provides methods for diagnosing the presence of colon cancer by analyzing for changes in levels of CSG in cells, tissues or bodily fluids compared with levels

- 7 -

of CSG in cells, tissues or bodily fluids of preferably the same type from a normal human control, wherein an increase in levels of CSG in the patient versus the normal human control is associated with the presence of colon cancer.

5 Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the patient being tested has cancer is one in which cells, tissues, or bodily fluid levels of the cancer marker, such as CSG, are at least two times higher, and most preferable are
10 at least five times higher, than in preferably the same cells, tissues, or bodily fluid of a normal human control.

The present invention also provides a method of diagnosing metastatic colon cancer in a patient having colon cancer which has not yet metastasized for the onset of
15 metastasis. In the method of the present invention, a human cancer patient suspected of having colon cancer which may have metastasized (but which was not previously known to have metastasized) is identified. This is accomplished by a variety of means known to those of skill in the art. For
20 example, in the case of colon cancer, patients are typically diagnosed with colon cancer following traditional detection methods.

In the present invention, determining the presence of CSG level in cells, tissues, or bodily fluid, is particularly
25 useful for discriminating between colon cancer which has not metastasized and colon cancer which has metastasized. Existing techniques have difficulty discriminating between colon cancer which has metastasized and colon cancer which has not metastasized and proper treatment selection is often
30 dependent upon such knowledge.

In the present invention, the cancer marker levels measured in such cells, tissues, or bodily fluid is CSG, and are compared with levels of CSG in preferably the same cells, tissue, or bodily fluid type of a normal human control. That
35 is, if the cancer marker being observed is just CSG in serum,

- 8 -

this level is preferably compared with the level of CSG in serum of a normal human patient. An increase in the CSG in the patient versus the normal human control is associated with colon cancer which has metastasized.

5 Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the cancer in the patient being tested or monitored has metastasized is one in which cells, tissues, or bodily fluid levels of the cancer marker, such as CSG, are at least two
10 times higher, and most preferable are at least five times higher, than in preferably the same cells, tissues, or bodily fluid of a normal patient.

Normal human control as used herein includes a human patient without cancer and/or non cancerous samples from the
15 patient; in the methods for diagnosing metastasis or monitoring for metastasis, normal human control preferably includes samples from a human patient that is determined by reliable methods to have colon cancer which has not metastasized such as earlier samples from the same patient
20 prior to metastasis.

Staging

The invention also provides a method of staging colon cancer in a human patient.

The method comprises identifying a human patient having
25 such cancer; analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG. Then, the method compares CSG levels in such cells, tissues, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in
30 CSG levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CSG is associated with a cancer which is regressing or in remission.

Monitoring

Further provided is a method of monitoring colon cancer in a human having such cancer for the onset of metastasis. The method comprises identifying a human patient having such
5 cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissue, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human
10 control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

Further provided by this inventions is a method of monitoring the change in stage of colon cancer in a human
15 having such cancer. The method comprises identifying a human patient having such cancer; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissue, or bodily fluid with levels of CSG in preferably the same cells,
20 tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease in the levels of CSG is associated with a cancer which is regressing in stage
25 or in remission.

Monitoring such patient for onset of metastasis is periodic and preferably done on a quarterly basis. However, this may be more or less frequent depending on the cancer, the particular patient, and the stage of the cancer.

30 Assay Techniques

Assay techniques that can be used to determine levels of gene expression, such as CSG of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays,

- 10 -

reverse transcriptase PCR (RT-PCR) assays, immunohistochemistry assays, *in situ* hybridization assays, competitive-binding assays, Western Blot analyses, ELISA assays and proteomic approaches. Among these, ELISAs are
5 frequently preferred to diagnose a gene's expressed protein in biological fluids.

An ELISA assay initially comprises preparing an antibody, if not readily available from a commercial source, specific to CSG, preferably a monoclonal antibody. In addition a
10 reporter antibody generally is prepared which binds specifically to CSG. The reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or enzymatic reagent, for example horseradish peroxidase enzyme or alkaline phosphatase.

15 To carry out the ELISA, antibody specific to CSG is incubated on a solid support, e.g., a polystyrene dish, that binds the antibody. Any free protein binding sites on the dish are then covered by incubating with a non-specific protein such as bovine serum albumin. Next, the sample to be
20 analyzed is incubated in the dish, during which time CSG binds to the specific antibody attached to the polystyrene dish. Unbound sample is washed out with buffer. A reporter antibody specifically directed to CSG and linked to horseradish peroxidase is placed in the dish resulting in binding of the
25 reporter antibody to any monoclonal antibody bound to CSG. Unattached reporter antibody is then washed out. Reagents for peroxidase activity, including a colorimetric substrate are then added to the dish. Immobilized peroxidase, linked to CSG antibodies, produces a colored reaction product. The amount
30 of color developed in a given time period is proportional to the amount of CSG protein present in the sample. Quantitative results typically are obtained by reference to a standard curve.

A competition assay may be employed wherein antibodies
35 specific to CSG attached to a solid support and labeled CSG

- 11 -

and a sample derived from the host are passed over the solid support and the amount of label detected attached to the solid support can be correlated to a quantity of CSG in the sample.

Nucleic acid methods may be used to detect CSG mRNA as
5 a marker for colon cancer. Polymerase chain reaction (PCR) and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASABA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example, reverse-
10 transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse
15 transcriptase; the cDNA is then amplified as in a standard PCR reaction. RT-PCR can thus reveal by amplification the presence of a single species of mRNA. Accordingly, if the mRNA is highly specific for the cell that produces it, RT-PCR can be used to identify the presence of a specific type of
20 cell.

Hybridization to clones or oligonucleotides arrayed on a solid support (i.e., gridding) can be used to both detect the expression of and quantitate the level of expression of that gene. In this approach, a cDNA encoding the CSG gene
25 is fixed to a substrate. The substrate may be of any suitable type including but not limited to glass, nitrocellulose, nylon or plastic. At least a portion of the DNA encoding the CSG gene is attached to the substrate and then incubated with the analyte, which may be RNA or a complementary DNA (cDNA) copy
30 of the RNA, isolated from the tissue of interest. Hybridization between the substrate bound DNA and the analyte can be detected and quantitated by several means including but not limited to radioactive labeling or fluorescence labeling of the analyte or a secondary molecule designed to detect the
35 hybrid. Quantitation of the level of gene expression can be

09752021.000601

- 12 -

done by comparison of the intensity of the signal from the analyte compared with that determined from known standards. The standards can be obtained by *in vitro* transcription of the target gene, quantitating the yield, and then using that
5 material to generate a standard curve.

Of the proteomic approaches, 2D electrophoresis is a technique well known to those in the art. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by
10 different characteristics usually on polyacrylamide gels. First, proteins are separated by size using an electric current. The current acts uniformly on all proteins, so smaller proteins move farther on the gel than larger proteins. The second dimension applies a current perpendicular to the
15 first and separates proteins not on the basis of size but on the specific electric charge carried by each protein. Since no two proteins with different sequences are identical on the basis of both size and charge, the result of a 2D separation is a square gel in which each protein occupies a unique spot.
20 Analysis of the spots with chemical or antibody probes, or subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample.

The above tests can be carried out on samples derived
25 from a variety of patients' cells, bodily fluids and/or tissue extracts (homogenates or solubilized tissue) such as from tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva, or any other bodily secretion or derivative thereof. Blood can
30 include whole blood, plasma, serum, or any derivative of blood.

In Vivo Antibody Use

Antibodies against CSG can also be used *in vivo* in patients with diseases of the colon. Specifically, antibodies

- 13 -

against an CSG can be injected into a patient suspected of having a disease of the colon for diagnostic and/or therapeutic purposes. The use of antibodies for *in vivo* diagnosis is well known in the art. For example, antibody-
5 chelators labeled with Indium-111 have been described for use in the radioimmunoscentographic imaging of carcinoembryonic antigen expressing tumors (Sumerdon et al. Nucl. Med. Biol. 1990 17:247-254). In particular, these antibody-chelators have been used in detecting tumors in patients suspected of
10 having recurrent colorectal cancer (Griffin et al. J. Clin. Onc. 1991 9:631-640). Antibodies with paramagnetic ions as labels for use in magnetic resonance imaging have also been described (Lauffer, R.B. Magnetic Resonance in Medicine 1991 22:339-342). Antibodies directed against CSGs can be used in
15 a similar manner. Labeled antibodies against an CSG can be injected into patients suspected of having a disease of the colon such as colon cancer for the purpose of diagnosing or staging of the disease status of the patient. The label used will be selected in accordance with the imaging modality to
20 be used. For example, radioactive labels such as Indium-111, Technetium-99m or Iodine-131 can be used for planar scans or single photon emission computed tomography (SPECT). Positron emitting labels such as Fluorine-19 can be used in positron emission tomography. Paramagnetic ions such as Gadlinium
25 (III) or Manganese (II) can used in magnetic resonance imaging (MRI). Localization of the label within the colon or external to the colon permits determination of the spread of the disease. The amount of label within the colon also allows determination of the presence or absence of cancer in the
30 colon.

For patients diagnosed with colon cancer, injection of an antibody against a CSG can also have a therapeutic benefit. The antibody may exert its therapeutic effect alone. Alternatively, the antibody is conjugated to a cytotoxic agent
35 such as a drug, toxin or radionuclide to enhance its

- 14 -

therapeutic effect. Drug monoclonal antibodies have been described in the art for example by Garnett and Baldwin, Cancer Research 1986 46:2407-2412. The use of toxins conjugated to monoclonal antibodies for the therapy of various
5 cancers has also been described by Pastan et al. Cell 1986 47:641-648). Yttrium-90 labeled monoclonal antibodies have been described for maximization of dose delivered to the tumor while limiting toxicity to normal tissues (Goodwin and Meares Cancer Supplement 1997 80:2675-2680). Other cytotoxic
10 radionuclides including, but not limited to Copper-67, Iodine-131 and Rhenium-186 can also be used for labeling of antibodies against CSGs.

Antibodies which can be used in these *in vivo* methods include both polyclonal and monoclonal antibodies and
15 antibodies prepared via molecular biology techniques. Antibody fragments and aptamers and single-stranded oligonucleotides such as those derived from an *in vitro* evolution protocol referred to as SELEX and well known to those skilled in the art can also be used.

20 EXAMPLES

The present invention is further described by the following example. The example is provided solely to illustrate the invention by reference to specific embodiments. These exemplifications, while illustrating certain specific
25 aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention.

Example 1

Identification of CSGs were carried out by a systematic analysis of data in the LIFESEQ database available from Incyte
30 Pharmaceuticals, Palo Alto, CA, using the data mining Cancer Leads Automatic Search Package (CLASP) developed by diaDexus LLC, Santa Clara, CA.

- 15 -

The CLASP performs the following steps:

Selection of highly expressed organ specific genes based on the abundance level of the corresponding EST in the targeted organ versus all the other organs.

- 5 Analysis of the expression level of each highly expressed organ specific genes in normal, tumor tissue, disease tissue and tissue libraries associated with tumor or disease.

Selection of the candidates demonstrating component ESTs were exclusively or more frequently found in tumor libraries.

- 10 CLASP allows the identification of highly expressed organ and cancer specific genes useful in the diagnosis of colon cancer.

Table 1: CSGs Sequences

| | SEQ ID NO: | LS Clone ID | LSA Gene ID |
|----|------------|-------------|-------------|
| 15 | 1 | 1517021 | 236347 |
| | 2 | 776410 | 202109 |
| | 3 | 611082 | 202298 |

- The following Example was carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. Routine molecular biology techniques of the following example can be carried out as described in standard laboratory manuals, such as Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).
- 20
- 25

Example 2: Relative Quantitation of Gene Expression

- Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5'- 3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected
- 30

- 16 -

by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA).

Amplification of an endogenous control was used to standardize the amount of sample RNA added to the reaction and
5 normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 18S ribosomal RNA (rRNA) was used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were
10 used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

The tissue distribution and the level of the target gene
15 was evaluated for every example in normal and cancer tissue. Total RNA was extracted from normal tissues, cancer tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently, first strand cDNA was prepared with reverse transcriptase and the polymerase chain reaction was
20 done using primers and Taqman probe specific to each target gene. The results are analyzed using the ABI PRISM 7700 Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.

25 **Comparative Examples**

Similar mRNA expression analysis for genes coding for the diagnostic markers PSA (Prostate Specific Antigen) and PLA2 (Phospholipase A2) was performed for comparison. PSA is the only cancer screening marker available in clinical
30 laboratories. When the panel of normal pooled tissues was analyzed, PSA was expressed at very high levels in prostate, with a very low expression in breast and testis. After more than 55 matching samples from 14 different tissues were analyzed, the data corroborated the tissue specificity seen
35 with normal tissue samples. PSA expression was compared in

- 17 -

cancer and normal adjacent tissue for 12 matching samples of prostate tissue. The relative levels of PSA were higher in 10 cancer samples (83%). Clinical data recently obtained support the utilization of PLA2 as a staging marker for late stages of prostate cancer. mRNA expression data showed overexpression of the mRNA in 8 out of the 12 prostate matching samples analyzed (66%). The tissue specificity for PLA2 was not as good as the one described for PSA. In addition to prostate, also small intestine, liver, and pancreas showed high levels of mRNA expression for PLA2.

Measurement of SEQ ID NO: 1; Clone ID1517021; Gene ID236347 (Cln117)

The absolute numbers shown in Table 2 are relative levels of expression of Cln117 in 12 normal different tissues. All the values are compared to normal testis (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

Table 2: Relative levels of Cln117 Expression in Pooled Samples

| Tissue | NORMAL |
|-----------------|--------|
| Colon-Ascending | 238 |
| Endometrium | 0 |
| Kidney | 0.02 |
| Liver | 0 |
| Ovary | 0.23 |
| Pancreas | 0 |
| Prostate | 0.06 |
| Small Intestine | 35 |
| Spleen | 0.0 |
| Stomach | 16 |
| Testis | 1 |
| Uterus | 0.06 |

The relative levels of expression in Table 2 show that Cln117 mRNA expression is higher (238) in colon compared with all the other normal tissues analyzed. Small intestine, with a relative expression level of 35, and stomach with 16 are the

only other tissues expressing mRNA for Cln117. These results establish that Cln117 mRNA expression is highly specific for tissues from the digestive system.

The absolute numbers in Table 2 were obtained analyzing 5 pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 3.

The absolute numbers depicted in Table 3 are relative 10 levels of expression of Cln117 in 75 pairs of matching samples. All the values are compared to normal testis (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

15 Table 3: Relative levels of Cln117 Expression in Individual Samples

| Sample ID | Cancer Type | Tissue | Cancer | Matching Normal |
|-------------|-------------------------------|-------------------|--------|-----------------|
| Sto AC93 | | Stomach 1 | 94 | 189 |
| 20 Sto AC99 | | Stomach 2 | 21 | 30 |
| Sto 539S | | Stomach 3 | 3 | 4 |
| Sto 728A | | Stomach 4 | 0.11 | 2 |
| Sto AC44 | | Stomach 5 | 20 | 28 |
| Sto MT54 | | Stomach 6 | 58 | 14 |
| 25 Sto TA73 | | Stomach 7 | 88 | 102 |
| Sto 288S | | Stomach 8 | 44 | 2 |
| SmI H89 | | Sm. Int. 1 | 101 | 167 |
| SmI 21XA | | Sm. Int. 2 | 62 | 15 |
| Cln AS45 | Adenocarcinoma Duke's Stage A | Colon-Ascending 1 | 45 | 57 |
| 30 Cln CM67 | Adenocarcinoma Duke's Stage B | Colon-Cecum 2 | 44 | 37 |

| | | | | | |
|----|----------|----------------------------------|------------------------------|-----|-----|
| 5 | Cln AS67 | Adenocarcinoma Duke's Stage B | Colon- Ascending 3 | 97 | 40 |
| | Cln AS43 | Adenocarcinoma Duke's Stage C | Colon- Ascending 4 | 143 | 39 |
| | Cln AS46 | Adenocarcinoma Duke's Stage C | Colon Ascending 5 | 214 | 182 |
| | Cln AS98 | Adenocarcinoma Duke's Stage C | Colon- Ascending 6 | 189 | 106 |
| | Cln B56 | Adenocarcinoma Duke's Stage C | Colon-Cecum 7 | 89 | 143 |
| 10 | Cln AS89 | Adenocarcinoma Duke's Stage D | Colon- Ascending 8 | 45 | 10 |
| | Cln TX01 | Adenocarcinoma Duke's Stage B | Colon- Transverse 9 | 20 | 42 |
| | Cln TX89 | Adenocarcinoma Duke's Stage B | Colon- Transverse 10 | 32 | 17 |
| | Cln TX67 | Adenocarcinoma Duke's Stage C | Colon- Transverse 11 | 23 | 30 |
| | Cln MT38 | Adenocarcinoma Duke's Stage D | Colon-Splenic flexure 12 | 87 | 82 |
| 15 | Cln SG36 | Adenocarcinoma Duke's Stage B | Colon-Sigmoid 13 | 173 | 144 |
| | Cln SG27 | Adenocarcinoma Duke's Stage B | Colon-Sigmoid 14 | 79 | 76 |
| | Cln SG89 | Adenocarcinoma Duke's Stage B | Colon-Sigmoid 15 | 57 | 56 |
| | Cln SG67 | Adenocarcinoma Duke's Stage C | Colon-Sigmoid 16 | 20 | 19 |
| | Cln SG33 | Adenocarcinoma Duke's Stage C | Colon-Sigmoid 17 | 125 | 223 |
| | Cln SG45 | Adenocarcinoma Duke's Stage D | Colon-Sigmoid 18 | 62 | 48 |
| | Cln B34 | Adenocarcinoma Duke's Stage A | Colon- Rectosigmoid 19 | 37 | 11 |
| | Cln CXGA | Adenocarcinoma Duke's Stage A | Colon-Rectum 20 | 201 | 136 |
| | Cln RC67 | Adenocarcinoma Duke's Stage B | Colon-Rectum 21 | 15 | 52 |

T09080" T2029/60

- 20 -

| | | | | | |
|----|--------------|----------------------------------|------------------------------|------|------|
| | Cln SG98 | Adenocarcinoma Duke's Stage C | Colon- Rectosigmoid 22 | 40 | 58 |
| | Cln C9XR | Adenocarcinoma Duke's Stage C | Colon- Rectosigmoid 23 | 22 | 27 |
| | Cln RS45 | Adenocarcinoma Duke's Stage C | Colon- Rectosigmoid 24 | 269 | 112 |
| | Cln RC01 | Adenocarcinoma Duke's Stage C | Colon-Rectum 25 | 19 | 62 |
| 5 | Cln RC89 | Adenocarcinoma Duke's Stage D | Colon-Rectum 26 | 0.36 | 44 |
| | Cln RC24 | Adenocarcinoma Duke's Stage D | Colon-Rectum 27 | 91 | 77 |
| | Bld 32XK | | Bladder 1 | 0.82 | 0 |
| | Bld 46XK | | Bladder 2 | 0 | 0.25 |
| | Bld 66X | | Bladder 3 | 0.35 | 0 |
| 10 | Cvx NKS54 | | Cervix 1 | 0.31 | 0 |
| | Cvx KS52 | | Cervix 2 | 0 | 0 |
| | Cvx NK24 | | Cervix 3 | 0.23 | 0 |
| | End 4XA | | Endometrium 1 | 0 | 0 |
| 15 | End 8911 | | Endometrium 2 | 0.04 | 1.24 |
| | End 8XA | | Endometrium 3 | 0.08 | 4 |
| | Kid 5XD | | Kidney 1 | 0.92 | 1.67 |
| | Kid 6XD | | Kidney 2 | 0.30 | 0.02 |
| 20 | Kid 106XD | | Kidney 3 | 0 | 0.06 |
| | Kid 126XD | | Kidney 4 | 0 | 0 |
| | Kid 12XD | | Kidney 5 | 0 | 0 |
| | Liv 42X | | Liver 1 | 50 | 0 |
| 25 | Liv 15XA | | Liver 2 | 16 | 0.19 |
| | Liv 94XA | | Liver 3 | 0.37 | 0.04 |

T03080 "T0009"60

| | | | | | |
|----|--------------|--|--------------------|--------|-------|
| | Lng AC69 | | Lung 1 | 0.41 | 0 |
| | Lng BR94 | | Lung 2 | 0.05 | 0 |
| | Lng 47XQ | | Lung 3 | 0 | 0 |
| | Lng 90X | | Lung 4 | 0 | 0 |
| 5 | Mam 59X | | Mammary Gland 1 | 0 | 0 |
| | Mam 12X | | Mammary Gland 2 | 0 | 0 |
| | Mam B011X | | Mammary Gland 3 | 0 | 0 |
| | Mam A06X | | Mammary Gland 4 | 0.02 | 0 |
| 10 | Ovr 103X | | Ovary 1 | 0.01 | 0.021 |
| | Pan 71XL | | Pancreas 1 | 114.56 | 123 |
| | Pan 77X | | Pancreas 2 | 0.18 | 0.09 |
| | Pan 92X | | Pancreas 3 | 146 | 0.30 |
| | Pan 82XP | | Pancreas 4 | 0.02 | 0 |
| 15 | Pro 109XB | | Prostate 1 | 0 | 0.01 |
| | Pro 34B | | Prostate 2 | 0 | 0.03 |
| | Pro 12B | | Prostate 3 | 0 | 0 |
| | Pro 23B | | Prostate 4 | 0 | 0.05 |
| 20 | Tst 39X | | Testis 1 | 1.60 | 0.60 |
| | Utr 85XU | | Uterus 1 | 0.21 | 0 |
| | Utr 141XO | | Uterus 2 | 1.80 | 0 |
| | Utr 23XU | | Uterus 3 | 1.36 | 0.07 |

25 0=negative

In the analysis of matching samples, the higher levels of expression were in colon, showing a high degree of tissue specificity for digestive system. Of all the samples different than colon analyzed, only four samples (the cancer samples for the matches of liver 1 and 2, and pancreas 1 and 3; and the normal adjacent for the pancreas match #1) showed

- 22 -

an expression comparable to the mRNA expression in colon. These results confirm the tissue specificity results obtained with the panel of normal pooled samples (Table 2).

Furthermore, the level of mRNA expression in cancer 5 samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 3 shows overexpression of Cln117 in 10 17 primary colon cancer tissues compared with their respective normal adjacent (colon samples #2, 3, 4, 5, 6, 8, 10, 12, 13, 14, 15, 16, 18, 19, 20, 24, and 27). There was overexpression in the cancer tissue for 63% of the colon matching samples tested (total of 27 colon matching samples).

15 Altogether, the high level of tissue specificity, plus the mRNA overexpression in 63% of the primary colon matching samples tested is demonstrative of Cln117 being a diagnostic marker for colon cancer.

Measurement of SEQ ID NO:2; Clone ID776410; Gene ID202109 20 (Cln124)

The absolute numbers depicted in Table 4 are relative levels of expression of Cln124 in 12 normal different tissues. All the values are compared to normal colon (calibrator). These RNA samples are commercially available pools, originated 25 by pooling samples of a particular tissue from different individuals.

Table 4: Relative levels of Cln124 Expression in Pooled Samples

| Tissue | NORMAL |
|-----------------|--------|
| Colon-Ascending | 10000 |
| Endometrium | 0 |
| Kidney | 0.2 |
| Liver | 0 |
| Ovary | 0 |
| Pancreas | 0 |
| Prostate | 0.3 |
| Small Intestine | 6 |

- 23 -

| | |
|---------|---|
| Spleen | 2 |
| Stomach | 0 |
| Testis | 1 |
| Uterus | 0 |

5 The relative levels of expression in Table 4 show that Cln124 mRNA expression is more than 1000 fold higher in the pool of normal colon (10000) compared to all the other tissues analyzed. These results demonstrate that Cln124 mRNA expression is highly specific for colon.

10 The absolute numbers in Table 4 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 5.

15 The absolute numbers depicted in Table 5 are relative levels of expression of Cln124 in 41 pairs of matching samples. All the values are compared to normal colon (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

20 **Table 5: Relative levels of Cln124 Expression in Individual Samples**

| Sample ID | Cancer Type | Tissue | Cancer | Matching Normal |
|----------------|-------------------------------|-------------------|--------|-----------------|
| 25 Sto MT54 | | Stomach 1 | 0 | 0 |
| SmI 21XA | | Sm. Int. 1 | 0 | 0 |
| Cln AS45 | Adenocarcinoma Duke's Stage A | Colon-Ascending 1 | 0.03 | 0.15 |
| Cln CM67 | Adenocarcinoma Duke's Stage B | Colon-Cecum 2 | 0.37 | 2.06 |
| Cln AS12 | Adenocarcinoma Duke's Stage B | Colon-Ascending 3 | 0.40 | 5.20 |
| 30 Cln AS43 | Adenocarcinoma Duke's Stage C | Colon-Ascending 4 | 0 | 0.10 |

| | | | | | |
|----|----------|----------------------------------|------------------------------|-------|------|
| | Cln AS46 | Adenocarcinoma Duke's Stage C | Colon Ascending 5 | 0.02 | 1.73 |
| | Cln AS98 | Adenocarcinoma Duke's Stage C | Colon- Ascending 6 | 0.17 | 1.58 |
| | Cln AC19 | Adenocarcinoma Duke's Stage D | Colon- Ascending 7 | 0.59 | 7.05 |
| | Cln TX01 | Adenocarcinoma Duke's Stage B | Colon- Transverse 8 | 0 | 1.53 |
| 5 | Cln MT38 | Adenocarcinoma Duke's Stage D | Colon-Splenic flexture 9 | 0.001 | 2.43 |
| | Cln DC19 | Adenocarcinoma Duke's Stage B | Colon- Descending 10 | 0.41 | 1.34 |
| | Cln DC63 | Adenocarcinoma Duke's Stage C | Colon- Descending 11 | 0.005 | 0.50 |
| | Cln DC22 | Adenocarcinoma Duke's Stage D | Colon- Descending 12 | 0.002 | 0.09 |
| | Cln SG36 | Adenocarcinoma Duke's Stage B | Colon-Sigmoid 13 | 0.03 | 0.81 |
| 10 | Cln SG20 | Adenocarcinoma Duke's Stage B | Colon-Sigmoid 14 | 0 | 1.64 |
| | Cln SG27 | Adenocarcinoma Duke's Stage B | Colon-Sigmoid 15 | 0.11 | 1.04 |
| | Cln SG89 | Adenocarcinoma Duke's Stage B | Colon-Sigmoid 16 | 0.11 | 1.07 |
| | Cln SG66 | Adenocarcinoma Duke's Stage C | Colon-Sigmoid 17 | 0 | 0.45 |
| | Cln SG67 | Adenocarcinoma Duke's Stage C | Colon-Sigmoid 18 | 0.02 | 0.04 |
| 15 | Cln SG33 | Adenocarcinoma Duke's Stage C | Colon-Sigmoid 19 | 0.03 | 1.00 |
| | Cln CXGA | Adenocarcinoma Duke's Stage A | Colon-Rectum 20 | 0.34 | 2.36 |
| | Cln RC24 | Adenocarcinoma Duke's Stage B | Colon-Rectum 21 | 0.86 | 1.64 |
| | Cln RS86 | Adenocarcinoma Duke's Stage B | Colon- Rectosigmoid 22 | 0.01 | 0.97 |

09/29/2001 10:29:40

| | | | | | |
|----|--------------|----------------------------------|------------------------------|------|------|
| 5 | Cln RS16 | Adenocarcinoma Duke's Stage B | Colon- Rectosigmoid 23 | 0.01 | 0.05 |
| | Cln SG98 | Adenocarcinoma Duke's Stage C | Colon- Rectosigmoid 24 | 0.43 | 2.77 |
| | Cln C9XR | Adenocarcinoma Duke's Stage C | Colon- Rectosigmoid 25 | 0.01 | 0.35 |
| | Cln RS53 | Adenocarcinoma Duke's Stage C | Colon- Rectosigmoid 26 | 0.01 | 1.60 |
| | Cln RS45 | Adenocarcinoma Duke's Stage C | Colon- Rectosigmoid 27 | 0.23 | 0.54 |
| | Cln RC24 | Adenocarcinoma Duke's Stage D | Colon-Rectum 28 | 0.86 | 1.64 |
| 10 | Bld 32XK | | Bladder 1 | 0 | 0 |
| | Cvx KS52 | | Cervix 1 | 0 | 0 |
| | End 10479 | | Endometrium 1 | 0 | 0 |
| | Kid 109XD | | Kidney 1 | 0 | 0 |
| 15 | Kid 107XD | | Kidney 2 | 0 | 0 |
| | Kid 106XD | | Kidney 3 | 0 | 0 |
| | Liv 15XA | | Liver 1 | 0 | 0 |
| | Lng 47XQ | | Lung 1 | 0 | 0 |
| 20 | Mam 12X | | Mammary Gland 1 | 0 | 0 |
| | Tst 39X | | Testis 1 | 0 | 0 |
| | Utr 85XU | | Uterus 1 | 0 | 0 |

0=negative

In the analysis of matching samples, the higher levels of expression were in colon showing a high degree of tissue specificity for colon tissue. These results confirm the

tissue specificity results obtained with normal pooled samples (Table 4).

Furthermore, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an indication of specificity for the cancer stage (e.g. lower levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 5 shows reduction of expression of Cln124 in 28 primary colon cancer samples compared with their respective normal adjacent. There is downregulation of Cln124 in the cancer tissue for all the colon matching samples tested (total of 28 primary colon matching samples).

Altogether, the high level of tissue specificity, plus the mRNA downregulation in 100% of the colon matching samples tested are demonstrative of Cln124 being a diagnostic marker for colon cancer.

Measurement of SEQ ID NO:3; Clone ID611082; Gene ID202298 (Cln125)

The absolute numbers depicted in Table 6 are relative levels of expression of Cln125 in 12 normal different tissues. All the values are compared to normal testis (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

Table 6: Relative levels of Cln125 Expression in Pooled Samples

| Tissue | NORMAL |
|-----------------|---------------|
| Colon-Ascending | 2486 |
| Endometrium | 0.8 |
| Kidney | 0 |
| Liver | 0 |
| Ovary | 1.3 |
| Pancreas | 0 |
| Prostate | 0 |
| Small Intestine | 0 |
| Spleen | 0 |
| Stomach | 0.5 |

- 27 -

| | |
|--------|---|
| Testis | 1 |
| Uterus | 0 |

The relative levels of expression in Table 6 show that Cln125 mRNA expression is higher (2486) in colon compared with all the other normal tissues analyzed. Ovary, with a relative expression level of 1.3, endometrium (0.8), and stomach (0.5) are the only other tissues expressing mRNA for Cln125. These results established that Cln125 mRNA expression is highly specific for colon.

The absolute numbers in Table 6 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 7.

The absolute numbers depicted in Table 7 are relative levels of expression of Cln125 in 75 pairs of matching samples. All the values are compared to normal testis (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

Table 7: Relative levels of Cln125 Expression in Individual Samples

| Sample ID | Cancer Type | Tissue | Cancer | Matching Normal |
|-----------|-------------|------------|--------|-----------------|
| Sto AC93 | | Stomach 1 | 1 | 2 |
| Sto AC99 | | Stomach 2 | 0 | 0 |
| Sto 539S | | Stomach 3 | 0 | 0 |
| Sto 728A | | Stomach 4 | 0 | 0 |
| Sto AC44 | | Stomach 5 | 0 | 0 |
| Sto MT54 | | Stomach 6 | 3 | 0 |
| Sto TA73 | | Stomach 7 | 0 | 0 |
| Sto 288S | | Stomach 8 | 0 | 0 |
| SmI H89 | | Sm. Int. 1 | 0 | 0.5 |

| | | | | | |
|----|----------|--------------------------------------|------------------------------|-----|------|
| | SmI 21XA | | Sm. Int. 2 | 1 | 0 |
| | Cln CM67 | Adenocarcinoma Duke's Stage B | Colon-Cecum 1 | 3 | 27 |
| | Cln AS12 | Adenocarcinoma Duke's Stage B | Colon- Ascending 2 | 106 | 1290 |
| | Cln AS43 | Adenocarcinoma Duke's Stage C | Colon- Ascending 3 | 0 | 131 |
| 5 | Cln AS46 | Adenocarcinoma Duke's Stage C | Colon Ascending 4 | 0 | 461 |
| | Cln AS98 | Adenocarcinoma Duke's Stage C | Colon- Ascending 5 | 376 | 558 |
| | Cln B56 | Adenocarcinoma Duke's Stage C | Colon-Cecum 6 | 32 | 572 |
| | Cln AS89 | Adenocarcinoma Duke's Stage D | Colon- Ascending 7 | 3 | 0 |
| | Cln AC19 | Adenocarcinoma Duke's Stage D | Colon- Ascending 8 | 2 | 603 |
| 10 | Cln TX01 | Adenocarcinoma Duke's Stage B | Colon- Transverse 9 | 1 | 525 |
| | Cln TX89 | Adenocarcinoma Duke's Stage B | Colon- Transverse 10 | 5 | 401 |
| | Cln TX67 | Adenocarcinoma Duke's Stage C | Colon- Transverse 11 | 0 | 717 |
| | Cln MT38 | Adenocarcinoma Duke's Stage D | Colon-Splenic flecture 12 | 3 | 1562 |
| | Cln SG36 | Adenocarcinoma Duke's Stage B | Colon-Sigmoid 13 | 3 | 1073 |
| 15 | Cln SG20 | Adenocarcinoma Duke's Stage B | Colon-Sigmoid 14 | 2 | 1021 |
| | Cln SG27 | Adenocarcinoma Duke's Stage B | Colon-Sigmoid 15 | 207 | 951 |
| | Cln SG89 | Adenocarcinoma Duke's Stage B | Colon-Sigmoid 16 | 14 | 263 |
| | Cln SG67 | Adenocarcinoma Duke's Stage C | Colon-Sigmoid 17 | 18 | 32 |
| | Cln SG33 | Adenocarcinoma Duke's Stages C | Colon-Sigmoid 18 | 43 | 1075 |

T09050" T2029/60

| | | | | | |
|----|--------------|----------------------------------|------------------------------|-----|------|
| 5 | Cln B34 | Adenocarcinoma Duke's Stage A | Colon- Rectosigmoid 19 | 1 | 56 |
| | Cln CXGA | Adenocarcinoma Duke's Stage A | Colon-Rectum 20 | 95 | 1041 |
| | Cln RC67 | Adenocarcinoma Duke's Stage B | Colon-Rectum 21 | 32 | 207 |
| | Cln SG98 | Adenocarcinoma Duke's Stage C | Colon- Rectosigmoid 22 | 223 | 2781 |
| | Cln C9XR | Adenocarcinoma Duke's Stage C | Colon- Rectosigmoid 23 | 1 | 277 |
| | Cln RS45 | Adenocarcinoma Duke's Stage C | Colon- Rectosigmoid 24 | 535 | 513 |
| | Cln RC89 | Adenocarcinoma Duke's Stage D | Colon-Rectum 25 | 0 | 157 |
| | Cln RC24 | Adenocarcinoma Duke's Stage D | Colon-Rectum 26 | 232 | 346 |
| 10 | Bld 32XK | | Bladder 1 | 2 | 0 |
| | Bld 46XK | | Bladder 2 | 0 | 0 |
| | Bld 66X | | Bladder 3 | 0 | 0 |
| | Cvx NKS54 | | Cervix 1 | 0 | 0 |
| | Cvx KS52 | | Cervix 2 | 0 | 0 |
| 15 | Cvx NK24 | | Cervix 3 | 0 | 0 |
| | End 10479 | | Endometrium 1 | 0 | 0 |
| | End 8911 | | Endometrium 2 | 0 | 0 |
| | End 8XA | | Endometrium 3 | 0 | 0 |
| 20 | Kid 5XD | | Kidney 1 | 0 | 0 |
| | Kid 109XD | | Kidney 2 | 0 | 0 |
| | Kid 107XD | | Kidney 3 | 0 | 0 |
| 25 | Kid 6XD | | Kidney 4 | 0 | 0 |

| | | | | |
|----|-----------|-----------------|------|------|
| 5 | Kid 106XD | Kidney 5 | 0 | 0 |
| | Kid 126XD | Kidney 6 | 0 | 0 |
| | Kid 12XD | Kidney 7 | 0 | 0 |
| | Liv 42X | Liver 1 | 0 | 0 |
| | Liv 15XA | Liver 2 | 0 | 0 |
| 10 | Liv 94XA | Liver 3 | 0 | 0 |
| | Lng AC69 | Lung 1 | 0 | 0 |
| | Lng BR94 | Lung 2 | 0 | 0 |
| | Lng 47XQ | Lung 3 | 0 | 0 |
| | Lng 90X | Lung 4 | 0 | 0 |
| 15 | Mam 59X | Mammary Gland 1 | 0 | 0 |
| | Mam 12X | Mammary Gland 2 | 0 | 0 |
| | Mam B011X | Mammary Gland 3 | 0 | 0 |
| | Mam A06X | Mammary Gland 4 | 0 | 0 |
| | Pan 71XL | Pancreas 1 | 1 | 0.12 |
| 20 | Pan 77X | Pancreas 2 | 0 | 0 |
| | Pan 92X | Pancreas 3 | 0 | 0 |
| | Pan 82XP | Pancreas 4 | 0 | 0 |
| | Pro 109XB | Prostate 1 | 0 | 0 |
| | Pro 34B | Prostate 2 | 0.48 | 0.23 |
| 25 | Pro 12B | Prostate 3 | 0.36 | 0 |
| | Pro 23B | Prostate 4 | 0.33 | 0 |
| | Tst 39X | Testis 1 | 0 | 7.67 |
| | Utr 85XU | Uterus 1 | 0 | 0 |
| | Utr 141XO | Uterus 2 | 0 | 0 |
| 30 | Utr 23XU | Uterus 3 | 0 | 0 |

T050301 FEB 23/60

- 31 -

0=negative

In the analysis of matching samples, the higher levels of expression were in colon, showing a high degree of tissue specificity for colon tissue. Of all the samples different
5 than colon analyzed, only one sample (the cancer sample Liver 2 with 48.6) showed an expression comparable to the mRNA expression in colon. These results confirm the tissue specificity results obtained with the panel of normal pooled samples (Table 6).

10 Furthermore, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an indication of specificity for the cancer stage (e.g. higher or lower levels of mRNA expression in the cancer sample
15 compared to the normal adjacent). Table 7 shows the reduction of mRNA levels of Cln125 in 24 primary colon cancer tissues compared with their respective normal adjacent (colon samples #1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 25, and 26). There was overexpression in
20 the cancer tissue for two of the colon matching samples tested (total of 26 colon matching samples).

Altogether, the high level of tissue specificity, plus the dramatic reduction of mRNA levels of Cln125 in the majority (92%) of the colon cancer samples in the matching
25 pairs tested are demonstrative of Cln125 being a diagnostic marker for colon cancer.

09762031-030604

- 32 -

What is claimed is:

1. A method for diagnosing the presence of colon cancer in a patient comprising:

(a) measuring levels of CSG in cells, tissues or bodily fluids in said patient; and

(b) comparing the measured levels of CSG with levels of CSG in cells, tissues or bodily fluids from a normal human control, wherein an increase in measured levels of CSG in said patient versus normal human control is associated with the presence of colon cancer.

2. A method of diagnosing metastatic colon cancer in a patient comprising:

(a) identifying a patient having colon cancer that is not known to have metastasized;

(b) measuring CSG levels in a sample of cells, tissues, or bodily fluid from said patient for CSG; and

(c) comparing the measured CSG levels with levels of CSG in cell, tissue, or bodily fluid type of a normal human control, wherein an increase in measured CSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

3. A method of staging colon cancer in a patient having colon cancer comprising:

(a) identifying a patient having colon cancer;

(b) measuring CSG levels in a sample of cells, tissues, or bodily fluid from said patient; and

(c) comparing measured CSG levels with levels of CSG in cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in measured CSG levels in said patient versus the normal human control is associated with a cancer which is progressing and a decrease in the measured CSG levels is associated with a cancer which is regressing or in remission.

- 33 -

4. A method of monitoring colon cancer in a patient for the onset of metastasis comprising:

(a) identifying a patient having colon cancer that is not known to have metastasized;

5 (b) periodically measuring levels of CSG in samples of cells, tissues, or bodily fluid from said patient for CSG; and

(c) comparing the periodically measured CSG levels with levels of CSG in cells, tissues, or bodily fluid type of a normal human control, wherein an increase in any one of the
10 periodically measured CSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

5. A method of monitoring the change in stage of colon cancer in a patient comprising:

15 (a) identifying a patient having colon cancer;

(b) periodically measuring levels of CSG in cells, tissues, or bodily fluid from said patient for CSG; and

(c) comparing the periodically measured CSG levels with levels of CSG in cells, tissues, or bodily fluid type of a
20 normal human control, wherein an increase in any one of the periodically measured CSG levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission.

25 6. The method of claim 1, 2, 3, 4 or 5 wherein the CSG comprises SEQ ID NO:1, 2 or 3.

7. An antibody against an CSG wherein said CSG comprises SEQ ID NO:1, 2 or 3.

8. A method of imaging colon cancer in a patient
30 comprising administering to the patient an antibody of claim 7.

- 34 -

9. The method of claim 8 wherein said antibody is labeled with paramagnetic ions or a radioisotope.

10. A method of treating colon cancer in a patient comprising administering to the patient an antibody of claim 5 7.

11. The method of claim 10 wherein the antibody is conjugated to a cytotoxic agent.

09763034 080694
T29080 T2029/60

SEQUENCE LISTING

<110> Sun, Yongming
 Recipon, Herve
 Macina, Roberto A
 DIADEXUS LLC

<120> A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING,
 IMAGING AND TREATING COLON CANCER

<130> DEX-0039

<140>

<141>

<150> 60/095,231

<151> 1998-08-04

<160> 3

<170> PatentIn Ver. 2.0

<210> 1

<211> 1710

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (1704)

<400> 1

```

ggcagagcga ctgaagacca gcctgcagaa ggctotggag gaagagctgg agcaaagacc 60
tcgacttgga ggccctcagc caggccagga cagatggagg gggcctgcta tggaaaggcc 120
gctccctatg gagcaggcac gctatctgga gccggggatc cctccagaac agccccacca 180
gaggacccta gagcacagcc tcccaccatc cccaaggccc ctgccacgcc acaccagtgc 240
ccgagaacca agtgccttta ctctgcctcc tccaaggcgg tctcttccc ccgaggacc 300
agagagggac gaggaagtgc tgaaccatgt cctaagggac attgagctgt tcatgggaaa 360
gctggagaag gcccaggcaa agaccagcag gaagaagaaa tttgggaaaa aaaacaagga 420
ccagggaggt ctcaccagc caccgtacat tgactgcttc cagaagatca agtacagctt 480
caacctcctg ggaaggctgg ccacctggct gaaggagaca agtgcccctg agctcgtaca 540
catcctcttc aagtccctga acttcatcct ggccagggtg cctgaggctg gcctagcagc 600
ccaagtgatc tcaccctcc tcaccctaa agctatcaac ctgctacagt cctgtctaag 660
cccacctgag agtaaccttt ggatgggggtt gggcccagcc tggaccacta gccgggccga 720
ctggacaggc gatgagcccc tgccctacca acccacattc tcagatgact ggcaacttcc 780
agagccctcc agccaagcac ccttaggata ccaggacct gtttcccttc ggcggggaag 840
tcataggtta gggagcacct cacactttcc tcaggagaag acacacaacc atgacctca 900
gcctggggac cccaactcca ggccctccag ccccaaacct gccagccag ccctgaaaat 960

```

gcaagtcttg taogagtttg aagctaggaa cccacgggaa ctgactgtgg tccagggaga 1020
 gaagctggag gttctggacc acagcaagcg gtggtggctg gtgaagaatg aggcgggacg 1080
 gagcggctac attccaagca acatcctgga gccctacag ccggggaccc ctggggacca 1140
 gggccagtca ccctctcggg ttccaatgct tcgacttagc tcgaggcctg aagaggtcac 1200
 agactggctg caggcagaga acttctccac tgccacgggtg aggacacttg ggccctgac 1260
 ggggagccag ctacttcgca taagacctgg ggagctacag atgctatgtc cacaggaggc 1320
 cccacgaatc ctgtcccggc tggaggctgt cagaaggatg ctggggataa gcccttaggc 1380
 accagcttag acacctccaa gaaccaggcc ccgctgatgc aagatggcag atctgatacc 1440
 cattagagcc ccgagaattc ctcttctgga tccagtttg cagcaaacc cacccccag 1500
 ctacacacgc aaaaacaatg gacaggccca gaggtgaag caaacagtgt cccttctggc 1560
 tgtgttggag cctccccagt aaccacctat ttattttacc tctttcccaa acctggagca 1620
 tttatgccta ggcttgtcaa gaatctgttc agtccctctc cttctcaata aaagcatctt 1680
 caagcttgta aaaaaaaaaa taangataaa 1710

<210> 2

<211> 1109

<212> DNA

<213> Homo sapiens

<400> 2

gggaaccacc ttctgtagga cagtcaccag gccagatcca gaagcctctc taggctccag 60
 ctttctctgt ggaagatgac agcaattata gcaggaccct gccaggctgt cgaaaagatt 120
 ccgcaataaa actttgccag tgggaagtac ctagtgaac ggctaagat gccacttctt 180
 ctcatgtccc aggtctgagg ccctgtggtc cccatccttg ggagaagtca gctccagcac 240
 catgaagggc atcctcgttg ctggtatcac tgcagtgtt gttgcagctg tagaatctct 300
 gagctgcgtg cagtgttaatt catgggaaaa atcctgtgtc aacagcattg cctctgaatg 360
 tccctccat gccaacacca gctgtatcag ctccctcagcc agctcctctc tagagacacc 420
 agtcagatta taccagaata tggtctgtc agcggagaac tgcagtgagg agacacacat 480
 tacagccttc actgtccacg tgtctgtcga agaacacttt cattttgtaa gccagtgtctg 540
 ccaaggaaag gaatgcagca acaccagcga tgccctggac cctccctga agaactgtc 600
 cagcaacgca gagtgccttg cttgttatga atctaagga acttctgtc gtgggaagcc 660
 ctggaaatgc tatgaagaag aacagtgtgt ctttctagtt gcagaactta agaatgacat 720
 tgagtctaag agtctcgtgc tgaaaggctg ttccaacgtc agtaacgcca cctgtcagtt 780
 cctgtctggt gaaaacaaga ctcttgagg agtcatctt cgaaagttt agtgtgcaaa 840
 tgtaaacagc ttaaccccca cgtctgcacc aaccacttcc cacaacgtgg gctccaaagc 900
 ttccctctac ctcttgccc ttgccagcct ccttctctcg ggactgtgc cctgaggctc 960
 tggggctgca ctttgcccag caccctatt ctgcttctct gaggtccaga gcacccctg 1020
 cgggtgtgac accctctttc cctgtctctc ccggtttaac tgcccagtaa gtgggagtc 1080
 caggtctcca ggcaatgccg acagctgcc 1109

<210> 3

<211> 1141

<212> DNA

<213> Homo sapiens

<400> 3

cagagaaaga ggaaacatag aggtgccaaa ggaacaaaga cataatgatg tcatccaagc 60
 caacaagcca tgctgaagta aatgaaacca tacccaaccc ttaccacca agcagcttta 120

tggctcctgg atttcaacag cctctgggtt caatcaactt agaaaaccaa gctcaggggtg 180
 ctgagcgtgc tcagccctat ggcatcacat ctccgggaat ctttgctagc agtcaaccgg 240
 gtcaaggaaa tatacaaatg ataaatccaa gtgtgggaac agcagtaatg aactttaaag 300
 aagaagcaaa ggcactaggg gtgatccaga tcatggttgg attgatgcac attgggtttg 360
 gaattgtttt gtgtttaata tccttctctt ttagagaagt attaggtttt gcctctactg 420
 ctgttattgg tggataccca ttctgggtg gcctttcttt tattatctct ggctctctct 480
 ctgtgtcagc atccaaggag ctttcccggt gtctggtgaa aggcagcctg ggaatgaaca 540
 ttgttagtto tatcttggcc ttcataggag tgattctgct gctggtggat atgtgcatca 600
 atggggtagc tggccaagac tactgggccc tgctttctgg aaaaggcatt tcagccacgc 660
 tgatgatctt ctccctcttg gagttcttcg tagcttgtgc cacagcccat tttgccaacc 720
 aagcaaacac cacaaccaat atgtctgtcc tggttattcc aaatatgtat gaaagcaacc 780
 ctgtgacacc agcgtcttct tcagctcctc ccagatgcaa caactactca gctaattgcc 840
 ctaaatagta aaagaaaaag gggatcagc ctaatctcat ggagaaaaac tacttgcaaa 900
 aacttcttaa gaagatgtct tttattgtct acaatgattt ctagtcttta aaaactgtgt 960
 ttgagatttg tttttagggt ggctgctaata gatggctgta tctcccttca ctgtctcttc 1020
 ctacattacc actactacat gctggcaaag gtgaaggatc agaggactga aaaatgattc 1080
 tgcaactctc ttaaagttag aaatgtttct gttcatatta ctttttcctt aataaaatgt 1140
 c 1141

Docket No.
DEX-0150

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

A Novel Method of Diagnosing, Monitoring, Staging, Imaging and Treating Colon Cancer

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on 20 July 1999 as United States Application No. or PCT International

Application Number PCT/US99/16357

and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

| | | | |
|-------------------|--------------------|---------------------------------|--------------------------|
| _____ (Number) | _____ (Country) | _____ (Day/Month/Year Filed) | <input type="checkbox"/> |
| _____ (Number) | _____ (Country) | _____ (Day/Month/Year Filed) | <input type="checkbox"/> |
| _____ (Number) | _____ (Country) | _____ (Day/Month/Year Filed) | <input type="checkbox"/> |

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

60/095,231

4 August 1998

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)


(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of third inventor, if any

Roberto A. Macina

Third inventor's signature



Date

7/20/01

Residence

San Jose, California CA

Citizenship

Argentina

Post Office Address

85 Fortuna Avenue**San Jose, California 95136**

Full name of fourth inventor, if any

Fourth inventor's signature

Date

Residence

Citizenship

Post Office Address

Full name of fifth inventor, if any

Fifth inventor's signature

Date

Residence

Citizenship

Post Office Address

Full name of sixth inventor, if any

Sixth inventor's signature

Date

Residence

Citizenship

Post Office Address

T06080 "T06080" 06/01/01

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*



26259

PATENT TRADEMARK OFFICE

Send Correspondence to: **Jane Massey Licata or Kathleen A. Tyrrell**
Licata & Tyrrell
66 E. Main Street
Marlton, New Jersey 08053

Direct Telephone Calls to: *(name and telephone number)*
Jane Massey Licata or Kathleen A. Tyrrell - (856) 810-1515

| | |
|--|--------------------------|
| Full name of sole or first inventor Yongming Sun | |
| Sole or first inventor's signature <i>[Signature]</i> | Date 7-20-2001 |
| Residence San Jose, California CA | |
| Citizenship China | |
| Post Office Address 869 Winchester Boulevard, Apt. 260 | |
| San Jose, California 95128 | |

| | |
|--|------------------------|
| Full name of second inventor, if any Herve Recipon | |
| Second inventor's signature <i>[Signature]</i> | Date 7-23-01 |
| Residence San Francisco, California CA | |
| Citizenship France | |
| Post Office Address 85 Fortuna Avenue | |
| San Francisco, California 94115 | |